of metabolic syndrome such as type 2 diabetes. Based on the hypothesis that the dual agonists of PPARs and FFA1 would act as insulin sensitizers and secretagogues by simultaneous activation of PPARs and FFA1, we developed the design strategy to obtain dual PPARs/FFA1 agonist by hybrid FFA1 agonist 1 with PPARδ agonist 2 in consideration of their structural similarity. As expected, systematic exploration
游离
脂肪酸受体1(FFA1)和
过氧化物酶体增殖物激活受体(
PPARs)作为治疗代谢综合征(如2型糖尿病)的有效靶标引起了人们的兴趣。基于该假设,即
PPARs的和FFA1的双重激动剂将作为
胰岛素敏化剂和分泌由
PPARs的和FFA1的同时激活,我们开发了设计策略通过混合FFA1以获得双
PPARs的/ FFA1激动剂激动剂1与
PPARδ激动剂2在考虑它们的结构相似性。不出所料,系统探索结构-活性关系和分子模型可导致发现
铅化合物15,一种泛激动剂,在FFA1,
PPARγ和
PPARδ之间具有相对平衡的活性。剂量反应关系研究表明,泛激动剂15以剂量依赖的方式抑制了血糖
水平的波动。在ob / ob小鼠接受5天治疗期间,泛激动剂15(100 mg / kg)表现出持续的降血糖作用,甚至接近最先进的FFA1激动剂(
TAK-875,40 mg / kg),这可能是由于它的泛
PPARs / FFA1活性可同时调